社区获得性肺炎中的生物标志物与临床评分系统
Biomarkers and clinical scoring systems in community-acquired pneumonia.
作者信息
Karakioulaki Meropi, Stolz Daiana
机构信息
Department of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Basel, Switzerland.
出版信息
Ann Thorac Med. 2019 Jul-Sep;14(3):165-172. doi: 10.4103/atm.ATM_305_18.
Abstract
Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality.
摘要
社区获得性肺炎（CAP）是全球第三大常见死因。由于CAP的复杂性，目前临床预后和诊断对于评估疾病严重程度并不充分，这一点已得到广泛认可。为了确定初始治疗方案和适当的干预水平，已开发了多种严重程度临床评分和生物标志物。生物标志物和临床评分系统都有望确定宿主因素的不同方面以及对治疗的反应，以便医生能够进行准确的获益/风险评估，从而实现正确诊断和合理使用抗生素。本综述旨在强调各种实验室和临床参数在CAP中的预后和诊断准确性，并讨论降低CAP死亡率的前景。
相似文献
1
Biomarkers and clinical scoring systems in community-acquired pneumonia.社区获得性肺炎中的生物标志物与临床评分系统
Ann Thorac Med. 2019 Jul-Sep;14(3):165-172. doi: 10.4103/atm.ATM_305_18.
2
Community acquired bacterial pneumonia.社区获得性细菌性肺炎。
Expert Opin Pharmacother. 2010 Feb;11(3):361-74. doi: 10.1517/14656560903508770.
3
Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.社区获得性肺炎临床及实验室参数的诊断和预后准确性
BMC Infect Dis. 2007 Mar 2;7:10. doi: 10.1186/1471-2334-7-10.
4
Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.肺炎链球菌所致社区获得性肺炎的严重程度评分：5年经验
Int J Antimicrob Agents. 2004 Nov;24(5):485-90. doi: 10.1016/j.ijantimicag.2004.05.006.
5
Updating cut-off values of severity scoring systems for community-acquired pneumonia to orchestrate more predictive accuracy.更新社区获得性肺炎严重程度评分系统的截断值以提高预测准确性。
Ann Med. 2023 Dec;55(1):2202414. doi: 10.1080/07853890.2023.2202414.
6
Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers.预测社区获得性肺炎患者 ICU 收治率：临床评分与生物标志物。
Expert Rev Clin Pharmacol. 2012 Jul;5(4):445-58. doi: 10.1586/ecp.12.28.
7
Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.半定量降钙素原检测及常见生物标志物对社区获得性肺炎临床结局的预测价值。
Respir Care. 2014 Apr;59(4):564-73. doi: 10.4187/respcare.02807. Epub 2013 Oct 29.
8
Biomarkers and community-acquired pneumonia: tailoring management with biological data.生物标志物与社区获得性肺炎：利用生物学数据调整管理策略。
Semin Respir Crit Care Med. 2012 Jun;33(3):266-71. doi: 10.1055/s-0032-1315638. Epub 2012 Jun 20.
9
A nomogram based on the expression level of angiopoietin-like 4 to predict the severity of community-acquired pneumonia.基于血管生成素样蛋白 4 表达水平的列线图预测社区获得性肺炎严重程度。
BMC Infect Dis. 2023 Oct 11;23(1):677. doi: 10.1186/s12879-023-08648-4.
10
Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study.血清 suPAR 和 syndecan-4 水平可预测社区获得性肺炎的严重程度：一项前瞻性、多中心研究。
Crit Care. 2018 Jan 24;22(1):15. doi: 10.1186/s13054-018-1943-y.
引用本文的文献
1
Time-Lagged Effects of Hyperglycemia on Inflammation in Older Adults with Community-Acquired Pneumonia: Nutritional Insights and Personalized Intervention Windows.高血糖对社区获得性肺炎老年人炎症的时间滞后效应：营养见解与个性化干预时机
Clin Interv Aging. 2025 Aug 25;20:1359-1380. doi: 10.2147/CIA.S533728. eCollection 2025.
2
Relationship between scoring systems and inflammatory parameters with mortality in pneumonia: Acute Phase Reactant Index is new index.肺炎评分系统及炎症参数与死亡率的关系：急性期反应物指数是新指标。
Rev Assoc Med Bras (1992). 2025 Aug 8;71(7):e20250005. doi: 10.1590/1806-9282.20250005. eCollection 2025.
3
Eosinopenia as a predictor of clinical outcomes in hospitalized patients with community-acquired pneumonia: A retrospective cohort study.嗜酸性粒细胞减少作为社区获得性肺炎住院患者临床结局的预测指标：一项回顾性队列研究。
PLoS One. 2025 Mar 6;20(3):e0314336. doi: 10.1371/journal.pone.0314336. eCollection 2025.
4
CURB-65 and Long-Term Mortality of Community-Acquired Pneumonia: A Retrospective Study on Hospitalized Patients.CURB-65与社区获得性肺炎的长期死亡率：一项关于住院患者的回顾性研究
Cureus. 2023 Mar 12;15(3):e36052. doi: 10.7759/cureus.36052. eCollection 2023 Mar.
5
Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice.急性护理环境中疑似慢性阻塞性肺疾病加重的鉴别诊断：最佳实践。
Am J Respir Crit Care Med. 2023 May 1;207(9):1134-1144. doi: 10.1164/rccm.202209-1795CI.
6
Comparison of C-reactive protein concentrations in dogs with Bordetella bronchiseptica infection and aspiration bronchopneumonia.比较感染支气管败血波氏杆菌和吸入性支气管肺炎的犬的 C 反应蛋白浓度。
J Vet Intern Med. 2021 May;35(3):1519-1524. doi: 10.1111/jvim.16091. Epub 2021 Mar 12.
本文引用的文献
1
Procalcitonin Testing to Guide Antibiotic Therapy in Acute Upper and Lower Respiratory Tract Infections.降钙素原检测指导急性上下呼吸道感染的抗生素治疗。
JAMA. 2018 Mar 6;319(9):925-926. doi: 10.1001/jama.2018.0852.
2
Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms.社区获得性肺炎发病初期的炎症谱与发病时间有关。
Am J Respir Crit Care Med. 2018 Aug 1;198(3):370-378. doi: 10.1164/rccm.201709-1908OC.
3
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.降钙素原用于启动或停用急性呼吸道感染中的抗生素治疗。
Cochrane Database Syst Rev. 2017 Oct 12;10(10):CD007498. doi: 10.1002/14651858.CD007498.pub3.
4
Diagnostic value of procalcitonin and CRP in critically ill patients admitted with suspected sepsis.降钙素原和C反应蛋白在疑似脓毒症收住的重症患者中的诊断价值
J Dent Anesth Pain Med. 2015 Sep;15(3):135-140. doi: 10.17245/jdapm.2015.15.3.135. Epub 2015 Sep 30.
5
Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia.使用血清生物标志物和各种临床风险量表对社区获得性肺炎进行死亡率预测。
Scand J Clin Lab Invest. 2017 Nov;77(7):486-492. doi: 10.1080/00365513.2017.1344298. Epub 2017 Jul 5.
6
Biomarkers in Pediatric Community-Acquired Pneumonia.儿童社区获得性肺炎中的生物标志物
Int J Mol Sci. 2017 Feb 19;18(2):447. doi: 10.3390/ijms18020447.
7
Severe community-acquired pneumonia: optimal management.重症社区获得性肺炎：最佳管理方案
Curr Opin Infect Dis. 2017 Apr;30(2):240-247. doi: 10.1097/QCO.0000000000000349.
8
Procalcitonin in Severe Community-Acquired Pneumonia: Some Precision Medicine Ready for Prime Time.降钙素原在重症社区获得性肺炎中的应用：一些精准医学已准备好投入实际应用。
Chest. 2016 Oct;150(4):769-771. doi: 10.1016/j.chest.2016.07.017.
9
Robust classification of bacterial and viral infections via integrated host gene expression diagnostics.通过整合宿主基因表达诊断实现细菌和病毒感染的稳健分类。
Sci Transl Med. 2016 Jul 6;8(346):346ra91. doi: 10.1126/scitranslmed.aaf7165.
10
Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.中段肾上腺髓质素原（MR-proADM）在社区获得性肺炎患者中的预后价值：一项系统评价和荟萃分析。
BMC Infect Dis. 2016 May 26;16:232. doi: 10.1186/s12879-016-1566-3.
Zotero 插件